Tumor recurrence and hypertension persistence after successful pheochromocytoma operation

Hypertension

Volumn 29, Issue 5, 1997, Pages 1133-1139

  Plouin, Pierre François ^a   Chatellier, Gilles ^a   Fofol, Isabelle ^a   Corvol, Pierre ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

catecholamines; Hippel Lindau disease; metanephrine; multiple endocrine neoplasia type 2a; multiple endocrine neoplasia type 2b; neurofibromatosis 1; pheochromocytoma; recurrence

Indexed keywords

ADRENALIN; CATECHOLAMINE; METADRENALIN; NEUROPEPTIDE Y; NORADRENALIN;

ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE; VON HIPPEL LINDAU DISEASE;

EID: 0030940811     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.5.1133     Document Type: Article

References (36)

1. Bravo EL. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev. 1994;15:356-368.
2. Manger WM, Gifford RW Jr. Phaeochromocytoma: a clinical overview. In: Swales JD, ed. Textbook of Hypertension. Oxford, UK: Blackwell Scientific Publications; 1994:941-958.
3. Stenström G, Ernest I, Tisell LE. Long-term results in 64 patients operated upon for pheochromocytoma. Acta Med Scand. 1988;223: 345-352.
4. Modlin IM, Farndon JR, Shepherd A, Johnston IDA, Kennedy TL, Montgomery DAD, Welbourn RB. Phaeochromocytomas in 72 patients: clinical and diagnostic features, treatment and long term results. Br J Surg. 1979;66:456-465.
5. Scott HW, Halter SA. Oncologic aspects of pheochromocytoma: the importance of follow-up. Surgery. 1984;96:1061-1066.
6. van Heerden JA, Roland CF, Carney JA, Sheps SG, Grant CS. Long-term evaluation following resection of apparently benign pheochromocytoma(s) or paraganglioma(s). World J Surg. 1990;14: 325-329.
7. Pruszczyk P, Januszewicz W, Feltynowski T, Chodakowska J, Wocial B, Pachocki R, Nielubowicz J, Szostek M. Long term follow-up after surgical removal of pheochromocytoma: observations in 61 patients. Clin Exp Hypertens A. 1991;13:1179-1194.
8. Shapiro B, Sisson JC, Lloyd R, Nakajo M, Satterlee W, Beierwaltes WH. Malignant phaeochromocytoma: clinical, biochemical and scintigraphic characterization. Clin Endocrinol. 1984;20:189-203.
9. Guo JZ, Gong LS, Chen SX, Luo BY, Xu MY. Malignant pheochromocytoma: diagnosis and treatment in fifteen cases. J Hypertens. 1989;7:261-266.
10. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
11. Plouin PF, Duclos JM, Ménard J, Comoy E, Bohuon C, Alexandre JM. Biochemical tests for diagnosis of phaeochromocytoma: urinary versus plasma determinations. Br Med J. 1981;282:853-854.
12. Plouin PF, Chatellier G, Rougeot MA, Duclos JM, Pagny JY, Corvol P, Ménard J. Recent developments in pheochromocytoma diagnosis and imaging. Adv Nephrol. 1988;17:275-286.
13. Héron E, Chatellier G, Billaud E, Foos E, Plouin PF. The urinary metanephrine to creatinine ratio in the diagnosis of pheochromocytoma. Ann Intent Med. 1996;125:300-303.
14. Plouin PF, Azizi M, Day M, Duclos JM, Corvol P. The pathophysiological basis of current pheochromocytoma management. In: Pinsky MR, Dhainaut JFA, eds. Pathophysiologic Foundations of Critical Care. Baltimore. Md: Williams & Wilkins; 1992:917-924.
15. Jebara VA, Sousa M, Farge A, Acar C, Azizi M, Plouin PF, Corvol P, Chachques JC, Dervanian P, Fabiani JN, Deloche A, Carpentier A. Cardiac pheochromocytomas. Ann Thorac Surg. 1992;53:356-361.
16. Bertani-Dziedzic LM, Krstulovic AM, Dziedzic SW, Gitlow SE, Cerqueira S. Analysis of urinary metanephrines by reversed-phase high-performance liquid chromatography and electrochemical detection. Clin Chem Acta. 1981:110:1-8.
17. Grouzmann E, Comoy E, Bohuon C. Plasma NPY concentrations in patients with neuroendocrine tumors. J Clin Endocrinol Metab. 1989;64:808-813.
18. Neumann HPH, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B, Kirste G. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med. 1993;329:1531-1538.
19. Lubs MLE, Bauer MS, Formas ME, Djokic B. Lisch nodules in neurofibromatosis type 1. N Engl J Med. 1991;324:1264-1266.
20. WHO Study Group. Diabetes Mellitus. Geneva, Switzerland: World Health Organization; 1985. Technical report series 727.
21. Cox DR. Regression models and life tables. J R Stat Soc. 1972;Ser 634:187-202.
22. Pattarino F, Bouloux PM. The diagnosis of malignant pneochromocytoma. Clin Endocrinol. 1996;44:239-241.
23. Linnoila RI, Keiser HR, Steinberg SM, Lack EE. Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathological study of 120 cases including unusual histologic features. Hum Pathol. 1990;21:1168-1180.
24. Tippett PA, McEwan AJ, Ackery DM. A reevaluation of dopamine excretion in phaeochromocytoma. Clin Endocrinol. 1986;25: 401-410.
25. Plouin PF, Chatellier G, Grouzmann E, Azizi M, Denolle T, Comoy E, Corvol P. Plasma neuropeptide Y and catecholamine concentrations and urinary metanephrine excretion in patients with adrenal or ectopic phaeochromocytoma. J Hypertens. 1991;9(suppl 6):S272-S273.
26. Mulligan LM, Ponder BAJ. Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 1995; 80:1989-1995.
27. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Duan DSR, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Smith MA, Le Paslier D, Chumakov I, Cohen D, Chinault AC, Maher ER, Linehan WM, Zbar B, Lerman MI. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260: 1317-1320.
28. Xu W, Mulligan LM, Ponder MA, Liu L, Smith BA, Mathew CG, Ponder BA. Loss of NF1 alleles in phaeochromocytomas from patients with type 1 neurofihromatosis. Genes Chromosom Cancer. 1992;4:337-342.
29. Albanese CT, Wiener ES. Routine total adrenalectomy is not warranted in childhood familial pheochromocytoma. J Pediatr Surg. 1993;28:1248-1252.
30. Casanova S, Rosenberg-Bourgin M, Farkas D, Calmettes C, Feingold N, Heshmati HM, Cohen R, Conte-Devolx B, Guillausseau PJ, Houdent C, Bigorgne JC, Boiteau V, Caron J, Modigliani E. Phaeochromocytoma in multiple endocrine neoplasia type 2A: survey of 100 cases. Clin Endocrinol. 1993;38:531-537.
31. Mayo C. Paroxysmal hypertension with tumor of retroperitoneal nerve. JAMA. 1927;139:1047-1050.
32. Streeten DHP, Anderson GH, Wagner S. Effect of age on response of secondary hypertension to specific treatment. Am J Hypertens. 1990;3:360-365.
33. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED Jr, Sos TA, Atlas SA, Muller FB, Acevedo R, Ulick S, Laragh JH. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med. 1994;121:877-885.
34. Eng C. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med. 1996;335:943-951.
35. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau gene. JAMA. 1995;273:564-570.
36. Welch HG. Questions about the value of early intervention. N Engl J Med. 1996;334:1472-1473.